In final guidance issued today (27 February), NICE has recommended ranibizumab (Lucentis, Novartis) as an option for treating visual impairment caused by diabetic macular oedema (NICE)
Diabetes News Service
Glycosmedia is also available as an App:
For iPhone and iPad | For Android devices
Sponsorship and Advertising
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
